During an advisory committee review of its application for Rexista (oxycodone extended-release), Intellipharmaceutics International Inc. was unable to answer numerous questions about the safety and efficacy of the opioid, prompting panelists to question why the company had filed an application with limited data.
The committee's July 26 discussion provided a blueprint of sorts on what the company should do as it will likely have to go back to the drawing board to conduct more studies – and also
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?